181 related articles for article (PubMed ID: 24685545)
1. Synthesis and cytotoxic activity of nitric oxide-releasing isosteviol derivatives.
Wang TT; Liu Y; Chen L
Bioorg Med Chem Lett; 2014 May; 24(9):2202-5. PubMed ID: 24685545
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and cytotoxic evaluation of nitric oxide-releasing derivatives of isosteviol.
Liu Y; Wang T; Ling Y; Bao N; Shi W; Chen L; Sun J
Chem Biol Drug Des; 2017 Sep; 90(3):473-477. PubMed ID: 28122177
[TBL] [Abstract][Full Text] [Related]
3. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxic activity of MOM-ether analogs of isosteviol.
Malki A; Laha R; Bergmeier SC
Bioorg Med Chem Lett; 2014 Feb; 24(4):1184-7. PubMed ID: 24444475
[TBL] [Abstract][Full Text] [Related]
5. D-ring modified novel isosteviol derivatives: design, synthesis and cytotoxic activity evaluation.
Zhang T; Lu LH; Liu H; Wang JW; Wang RX; Zhang YX; Tao JC
Bioorg Med Chem Lett; 2012 Sep; 22(18):5827-32. PubMed ID: 22901386
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization and
Qi XX; Wang PP; Cui LT; Jin M; Zhao LX; Li G
J Asian Nat Prod Res; 2024 Jul; 26(7):812-823. PubMed ID: 38477295
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, cytotoxic activity evaluation and HQSAR study of novel isosteviol derivatives as potential anticancer agents.
Liu CJ; Yu SL; Liu YP; Dai XJ; Wu Y; Li RJ; Tao JC
Eur J Med Chem; 2016 Jun; 115():26-40. PubMed ID: 26994841
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, cytotoxic activity, and 2D- and 3D-QSAR studies of 19-carboxyl-modified novel isosteviol derivatives as potential anticancer agents.
Liu CJ; Zhang T; Yu SL; Dai XJ; Wu Y; Tao JC
Chem Biol Drug Des; 2017 Jun; 89(6):870-887. PubMed ID: 27878967
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of isosteviol triazole conjugates for cancer therapy.
Khaybullin RN; Zhang M; Fu J; Liang X; Li T; Katritzky AR; Okunieff P; Qi X
Molecules; 2014 Nov; 19(11):18676-89. PubMed ID: 25405286
[TBL] [Abstract][Full Text] [Related]
10. Syntheses, cytotoxic activity evaluation and HQSAR study of 1,2,3-triazole-linked isosteviol derivatives as potential anticancer agents.
Liu CJ; Liu YP; Yu SL; Dai XJ; Zhang T; Tao JC
Bioorg Med Chem Lett; 2016 Nov; 26(22):5455-5461. PubMed ID: 27777008
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.
Li D; Wang L; Cai H; Zhang Y; Xu J
Molecules; 2012 Jun; 17(6):7556-68. PubMed ID: 22710829
[TBL] [Abstract][Full Text] [Related]
12. Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents.
Zhu SL; Wu Y; Liu CJ; Wei CY; Tao JC; Liu HM
Eur J Med Chem; 2013 Jul; 65():70-82. PubMed ID: 23693151
[TBL] [Abstract][Full Text] [Related]
13. Novel antileukemic agents derived from tamibarotene and nitric oxide donors.
Bian H; Feng J; Li M; Xu W
Bioorg Med Chem Lett; 2011 Dec; 21(23):7025-9. PubMed ID: 22014829
[TBL] [Abstract][Full Text] [Related]
14. Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity.
Zhao J; Gou S; Sun Y; Fang L; Wang Z
Inorg Chem; 2012 Oct; 51(19):10317-24. PubMed ID: 22957695
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer evaluation of complex unsaturated isosteviol-derived triazole conjugates.
Khaybullin RN; Liang X; Cisneros K; Qi X
Future Med Chem; 2015; 7(18):2419-28. PubMed ID: 26653151
[TBL] [Abstract][Full Text] [Related]
16. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro cytotoxic activity evaluation of novel heterocycle bridged carbothioamide type isosteviol derivatives as antitumor agents.
Zhu SL; Wu Y; Liu CJ; Wei CY; Tao JC; Liu HM
Bioorg Med Chem Lett; 2013 Mar; 23(5):1343-6. PubMed ID: 23347685
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of C-19 Isosteviol Derivatives as Potent and Highly Selective Antiproliferative Agents.
Luan T; Cao LH; Deng H; Shen QK; Tian YS; Quan ZS
Molecules; 2018 Dec; 24(1):. PubMed ID: 30598028
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of glaucocalyxin A derivatives as potential anticancer agents.
Yang J; Liu Y; Xue C; Yu W; Zhang J; Qiao C
Eur J Med Chem; 2014 Oct; 86():235-41. PubMed ID: 25164762
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activities of the Novel Isosteviol Derivative 10C Against Liver Cancer.
Malki A; El-Sharkawy A; El Syaed M; Bergmeier S
Anticancer Res; 2017 Apr; 37(4):1591-1601. PubMed ID: 28373419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
